Forward Uses Technology to Enhance Experience at Doctor's Office
Forward is all about proactive versus reactive healthcare and at the center of it is founder and CEO Adrian Aoun. He joins Alyssa Julya Smith at Forward's Los Angeles location to talk about some of the benefits of Forward and how technology is being used to help with preventative healthcare.
He explains that Tesla's and iPhone's can predict when they're likely to break down and intervene to fix things before it happens and that should be the same with healthcare. Forward created
personalized health plans through an in-depth understanding of a person's genetics, blood test results, biomarkers and daily lifestyle.
Aoun also explains that Forward doesn't use insurance, but is based on a monthly membership cost that allows Forward to do full diagnostic tests without hidden fees or bills from blood work or other lab testing, explaining that it's all done in the office.
Kim Kardashian’s shapewear brand Skims has doubled its valuation to $3.2 billion. Investors have taken a bet on the success of this brand in the form of fresh funds for the two-year-old company.
McDonald's missed on both the top and bottom lines in its Q4 earnings, marking the fourth loss for the fast-food giant in the past eight quarters. It comes as higher costs from food to wages ate into the blue-chip company's profits. George Seay, CEO of investment advisor Annandale Capital, joined Wake Up with Cheddar to discuss the recent numbers and the better-than-expected success of the McPlant burger made with plant-based Beyond Meat. "They're changing with the times, and they have to," Seay noted. "You can just sell a Big Mac to everybody. There's a lot of people who don't want to eat a Big Mac anymore."
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
